BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34045189)

  • 1. STK11/LKB1 Loss of Function Is Associated with Global DNA Hypomethylation and
    Koenig MJ; Agana BA; Kaufman JM; Sharpnack MF; Wang WZ; Weigel C; Navarro FCP; Amann JM; Cacciato N; Arasada RR; Gerstein MB; Wysocki VH; Oakes C; Carbone DP
    Cancer Res; 2021 Aug; 81(16):4194-4204. PubMed ID: 34045189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
    Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
    J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
    Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
    Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
    Kitajima S; Ivanova E; Guo S; Yoshida R; Campisi M; Sundararaman SK; Tange S; Mitsuishi Y; Thai TC; Masuda S; Piel BP; Sholl LM; Kirschmeier PT; Paweletz CP; Watanabe H; Yajima M; Barbie DA
    Cancer Discov; 2019 Jan; 9(1):34-45. PubMed ID: 30297358
    [No Abstract]   [Full Text] [Related]  

  • 5. A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.
    Kaufman JM; Yamada T; Park K; Timmers CD; Amann JM; Carbone DP
    Cancer Res; 2017 Jan; 77(1):153-163. PubMed ID: 27821489
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
    Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo.
    Rackley B; Seong CS; Kiely E; Parker RE; Rupji M; Dwivedi B; Heddleston JM; Giang W; Anthony N; Chew TL; Gilbert-Ross M
    Commun Biol; 2021 Jan; 4(1):142. PubMed ID: 33514834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An LKB1-SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation.
    Murray CW; Brady JJ; Tsai MK; Li C; Winters IP; Tang R; Andrejka L; Ma RK; Kunder CA; Chu P; Winslow MM
    Cancer Discov; 2019 Nov; 9(11):1590-1605. PubMed ID: 31350327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
    Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
    Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
    Skoulidis F; Byers LA; Diao L; Papadimitrakopoulou VA; Tong P; Izzo J; Behrens C; Kadara H; Parra ER; Canales JR; Zhang J; Giri U; Gudikote J; Cortez MA; Yang C; Fan Y; Peyton M; Girard L; Coombes KR; Toniatti C; Heffernan TP; Choi M; Frampton GM; Miller V; Weinstein JN; Herbst RS; Wong KK; Zhang J; Sharma P; Mills GB; Hong WK; Minna JD; Allison JP; Futreal A; Wang J; Wistuba II; Heymach JV
    Cancer Discov; 2015 Aug; 5(8):860-77. PubMed ID: 26069186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting adhesion signaling in
    Gilbert-Ross M; Konen J; Koo J; Shupe J; Robinson BS; Wiles WG; Huang C; Martin WD; Behera M; Smith GH; Hill CE; Rossi MR; Sica GL; Rupji M; Chen Z; Kowalski J; Kasinski AL; Ramalingam SS; Fu H; Khuri FR; Zhou W; Marcus AI
    JCI Insight; 2017 Mar; 2(5):e90487. PubMed ID: 28289710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations.
    Fernandez P; Carretero J; Medina PP; Jimenez AI; Rodriguez-Perales S; Paz MF; Cigudosa JC; Esteller M; Lombardia L; Morente M; Sanchez-Verde L; Sotelo T; Sanchez-Cespedes M
    Oncogene; 2004 Jun; 23(29):5084-91. PubMed ID: 15077168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting PGM3 as a Novel Therapeutic Strategy in
    Lee H; Cai F; Kelekar N; Velupally NK; Kim J
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
    Frau M; Feo F; Pascale RM
    J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LKB1 loss links serine metabolism to DNA methylation and tumorigenesis.
    Kottakis F; Nicolay BN; Roumane A; Karnik R; Gu H; Nagle JM; Boukhali M; Hayward MC; Li YY; Chen T; Liesa M; Hammerman PS; Wong KK; Hayes DN; Shirihai OS; Dyson NJ; Haas W; Meissner A; Bardeesy N
    Nature; 2016 Nov; 539(7629):390-395. PubMed ID: 27799657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of cellular identity in common pre-clinical models of serine‑threonine kinase 11 (Liver kinase B1) loss.
    Karthikeyan SK; Gimbrone NT; Percy TR; Cress WD
    Cancer Treat Res Commun; 2021; 26():100286. PubMed ID: 33338855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5'-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer.
    Trojan J; Brieger A; Raedle J; Esteller M; Zeuzem S
    Gut; 2000 Aug; 47(2):272-6. PubMed ID: 10896921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
    Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
    J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rab3B enhances the stabilization of DDX6 to promote lung adenocarcinoma aggressiveness.
    Yao G; Yu S; Hou F; Xiao Z; Li G; Ji X; Wang J
    Mol Med; 2024 Jun; 30(1):75. PubMed ID: 38834947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.